John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.

Researchers focus on reversing the scarring that’s common to liver diseases.

Our Global Head of Precision Medicine in Oncology discusses her day-to-day work at Novartis.

Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.

Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.